Angiotensin Blockade Does Not Affect Fibrosis Progression in Recurrent Hepatitis C After Liver Transplantation

被引:7
|
作者
Guillaud, O.
Gurram, K. C.
Puglia, M.
Lilly, L.
Adeyi, O.
Renner, E. L.
Selzner, N.
机构
[1] Univ Toronto, Univ Hlth Network, Multiorgan Transplant Program, Toronto, ON M5G 2N2, Canada
[2] Univ Toronto, Univ Hlth Network, Dept Pathol, Toronto, ON M5G 2N2, Canada
关键词
RECEPTOR ANTAGONIST; DONOR AGE; NONALCOHOLIC STEATOHEPATITIS; NATURAL-HISTORY; STELLATE CELLS; RAT; INHIBITION; LOSARTAN; SURVIVAL; SYSTEM;
D O I
10.1016/j.transproceed.2013.01.067
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. Liver transplantation (LT) for hepatitis C virus (HCV)-related end-stage liver disease is impaired by universal disease recurrence and suboptimal response to antiviral therapy. Inhibition of angiotensin-II signalling by angiotensin-converting enzyme inhibitors (ACE-I) or angiotensin-II receptor blockers (ARB) decreases hepatic stellate cell activation in vitro and hepatic fibrogenesis in animal models. A single-center retrospective analysis suggested that angiotensin blockade (AB) inhibits fibrosis progression in recurrent HCV post-LT. This study assessed the effect of AB on fibrosis progression in an independent patient cohort. Methods. Chart review of all patients who underwent transplantation in our institution for HCV-related ESLD between January 2000 and February 2008 revealed 109 patients with >= 2 protocol liver biopsies and free of antiviral therapy post-LT up to the last biopsy analyzed; 27 of 109 patients were treated with ACE-I/ARB for >= 12 months, 82 were not. Fibrosis was staged using METAVIR. Results. Live-donor LT was more frequent in controls than in the AB group (25% vs 11%; P < .05). However, parameters known to affect outcome of recurrent HCV, including donor age, prevalence of diabetes, acute cellular rejection, and immunosuppression, were similar in both groups. Time between first and last biopsy (median, 23 months), stage of fibrosis, fibrosis progression rates (median 0.47 vs 0.45 unit/y; P = .46), and time to develop fibrosis stage >= 2 did not differ between groups. Results held true if deceased-donor LT were analyzed separately. Conclusion. Our study does not support the contention of a previous report that use of AB reduces fibrosis progression in recurrent HCV post-LT.
引用
收藏
页码:2331 / 2336
页数:6
相关论文
共 50 条
  • [21] Impact of sustained virologic response on liver fibrosis in recurrent hepatitis C after liver transplantation
    Mauro, E.
    Crespo, G.
    Londono, M. C.
    Diaz, A.
    Ruiz, P.
    Montironi, C.
    Lombardo, J.
    Sastre, L.
    Aguirre, J.
    Colmenero, J.
    Forns, X.
    Brunet, M.
    Navasa, M.
    JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S440 - S440
  • [22] A prospective evaluation of fibrosis progression in patients with recurrent hepatitis C virus following liver transplantation
    Yilmaz, Nevin
    Shiffman, Mitchell L.
    Stravitz, R. Todd
    Sterling, Richard K.
    Luketic, Velimir A.
    Sanyal, Arun J.
    Mills, A. Scott
    Contos, Melissa J.
    Coterell, Adrian
    Maluf, Daniel
    Posner, Marc P.
    Fisher, Robert A.
    LIVER TRANSPLANTATION, 2007, 13 (07) : 975 - 983
  • [23] SIROLIMUS DECREASES FIBROSIS PROGRESSION IN RECURRENT HEPATITIS C DISEASE POST-LIVER TRANSPLANTATION
    Tsunoda, Shirley
    Sarubbi, Christina
    Ho, Anh-Thu T.
    Hollenbach, Kathryn
    Chatfield, Eileen
    Khanna, Ajai
    Barry, Christopher T.
    Hart, Marquis E.
    Hassanein, Tarek
    HEPATOLOGY, 2009, 50 (04) : 590A - 590A
  • [24] IMPACT OF ATP-BINDING CASSETTE TRANSPORTER POLYMORPHISMS ON FIBROSIS PROGRESSION IN RECURRENT HEPATITIS C AFTER LIVER TRANSPLANTATION
    Cicinnati, V.
    Iacob, S.
    Wu, G.
    Dechene, A.
    Popescu, I.
    Gerken, G.
    Paul, A.
    Beckebaum, S.
    TRANSPLANT INTERNATIONAL, 2011, 24 : 57 - 58
  • [25] FIBROSIS PROGRESSION AND RECURRENT CIRRHOSIS AFTER LIVER TRANSPLANTATION.
    Zimmermann, Tim
    Otto, Carina
    Sprinzl, Martin F.
    Otto, Gerd
    Schuchmann, Marcus
    LIVER TRANSPLANTATION, 2008, 14 (07) : S86 - S86
  • [26] Aspirin may reduce liver fibrosis progression: Evidence from a multicenter retrospective study of recurrent hepatitis C after liver transplantation
    Poujol-Robert, Armelle
    Boelle, Pierre-Yves
    Conti, Filomena
    Durand, Francois
    Duvoux, Christophe
    Wendum, Dominique
    Paradis, Valerie
    Mackiewicz, Vincent
    Chazouilleres, Olivier
    Corpechot, Christophe
    Poupon, Raoul
    CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY, 2014, 38 (05) : 570 - 576
  • [27] Association of Genetic Variants With Rapid Fibrosis: Progression After Liver Transplantation for Hepatitis C
    Layden, Jennifer E.
    Tayo, Bamidele O.
    Cotler, Scott J.
    Clark, Nina M.
    Baraoidan, Kristine
    Friedman, Scott L.
    Cooper, Richard S.
    TRANSPLANTATION, 2014, 97 (10) : 1072 - 1078
  • [28] Hepatitis C virus recurrence after liver transplantation: biomarkers of disease and fibrosis progression
    Maluf, Daniel G.
    Archer, Kellie J.
    Villamil, Federico
    Stravitz, Richard Todd
    Mas, Valeria
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2010, 4 (04) : 445 - 458
  • [29] Cryoglobulinemia predicts rapid progression to severe fibrosis after liver transplantation for hepatitis C
    Rayhill, SC
    Schmidt, W
    Kirby, P
    Voigt, M
    Katz, D
    Labrecque, D
    Martinez, G
    Mitros, F
    Miller, R
    Stolpin, A
    Vorhies, M
    Mebus, R
    Warkentin, G
    Wu, YM
    GASTROENTEROLOGY, 2002, 122 (04) : A641 - A641
  • [30] Serum fibrosis markers can predict rapid fibrosis progression after liver transplantation for hepatitis C
    Pungpopong, Surakit
    Nunes, David P.
    Krishna, Murli
    Nakhleh, Raouf
    Chambers, Kyle
    Ghabril, Marwan
    Dickson, Rolland C.
    Hughes, Christopher B.
    Steers, Jeffery
    Nguyen, Justin H.
    Keaveny, Andrew P.
    LIVER TRANSPLANTATION, 2008, 14 (09) : 1294 - 1302